Ketofast Ketofast

ADVERTISEMENT

Big Pharma's Dirty Marketing Tricks Not Limited to U.S.

Consider this blog posting just another in a seemingly never-ending series of reminders about the "dirty tricks" major pharmaceutical companies -- this time GlaxoSmithKline -- use to make consumers dependent on their worthless products. This time, a 250-page report revealed Glaxo's plans to double sales of its anti-depressant Seroxat (which has been linked to a number of suicides in the U.K.) by marketing it as a cure-all for numerous less serious mental conditions.

A section of the report, entitled, "Towards the second billion - all SSRIs are not the same," reveals how Glaxo wanted to double sales of Seroxat by winning the marketing war against Seroxat's chief rival, Prozac, manufacured by Eli Lilly. The report was first written six years ago and updated in subsequent years.

According to one scientist, the plan demonstrated how different forms of anxiety were being targeted in a systematic way. In other words, Glaxo was attempting to move product by pushing it to people who were not clinically depressed, including those who have social anxiety disorder, in a deliberate effort to double sales to the $2 billion mark.

In fact, one marketing "benefit" of Seroxat was its touted ability to allow patients to drop and reuse the drug easily, a controversial issue because the drug has been found to cause a dependency reaction in the body.

Keeping you posted on some of the more sorted details of these drug company sheningans is merely one of the many reasons I've stayed the course on my quest to transform the existing medical paradigm from one addicted to methods that only conceal or remove specific symptoms -- with morbid results to our health and economy -- to one focused on treating and preventing the underlying causes.

The Guardian November 7, 2004

Click Here and be the first to comment on this article
Post your comment